Manali Bhave, MD
Medical Oncology · Chicago, ILNPI 1699069880
Payments from drug & device makers
Across 548 payments — averaging $5954.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.2M
- Daiichi Sankyo Inc.$579K
- Daiichi Sankyo Company LTD$421K
- Exelixis Inc.$337K
- Incyte Corporation$261K
- Pfizer$179K
- plus $299K from 10 others
Across 6 payments — averaging $648.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 22 | $1,186,903 |
| Daiichi Sankyo Inc. | 66 | $578,735 |
| Daiichi Sankyo Company LTD | 48 | $421,268 |
| Exelixis Inc. | 162 | $337,331 |
| Incyte Corporation | 128 | $261,097 |
| Pfizer | 58 | $179,190 |
| Puma Biotechnology, Inc. | 34 | $133,131 |
| AstraZeneca | 12 | $99,484 |
| Merck | 3 | $53,645 |
| Lilly USA, LLC | 3 | $5,250 |
| Novartis | 3 | $4,343 |
| Gilead | 4 | $1,278 |
| Astrazeneca UK Limited | 2 | $1,245 |
| Johnson & Johnson | 1 | $113 |
| Stemline Therapeutics Inc. | 1 | $70 |
| Tempus AI, Inc | 1 | $30 |
How this compares
$3,263,113 in reported general payments places this provider in the 95th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
- Jeffrey SosmanChicago$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.